Rhein Biotech GmbH [Dynavax Europe], a subsidiary of Dynavax Technologies Corporation headquartered in Düsseldorf, Germany, develops, manufactures, licenses-out and markets biopharmaceutical products and technologies. Dynavax Europe was formed following the acquisition of Rhein Biotech GmbH by Dynavax Technologies in April 2006. Dynavax Europe has established an integrated portfolio of proprietary assets
* Product development expertise
* Products in the market (licensed-out & partnered)
* Platform of basic technologies
* Unique combination of vaccine, adjuvant and immune modulator know-how
* Quality-driven, industrial infrastructure (GLP, GMP)
* Expertise in technology transfer from and to collaboration partners
EU-GMP manufacturing license for biopharmaceuticals for clinical and commercial use.
Dynavax Europe's Business Model
Dynavax Europe has pursued a business model that combines development of proprietary biopharmaceutical products and establishing strategic alliances designed to leverage and add value to its core capabilities in the areas of process, analytical and preclinical development, quality control, quality assurance, manufacturing and technology transfer.
Through marketing and sales of recombinant antigens on the diagnostic market, Dynavax Europe leverages the value of the established vaccine production technologies.
In the course of the development of recombinant hepatitis B vaccines, Dynavax Europe has established the production of different subtypes of hepatitis B virus antigens of high purity and quality. Since 2001 Dynavax Europe has entered into supply contracts for hepatitis B antigens with three major, international diagnostic companies.